The economics of adalimumab for ulcerative colitis.
Expert Rev Pharmacoecon Outcomes Res
; 15(3): 373-7, 2015 Jun.
Article
em En
| MEDLINE
| ID: mdl-25817776
Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab, as a TNF-α blocker, offers a safe and efficacious treatment option for patients with moderate to severe ulcerative colitis and refractory or intolerant to conventional medications; however, its cost-effectiveness profile has not yet been well established. Future economic evaluations should choose appropriate comparators in the context of target-reimbursement decision making and focus on cost-effectiveness over a long time horizon.
Palavras-chave
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
/
Avaliacao_economica
Bases de dados:
MEDLINE
Assunto principal:
Colite Ulcerativa
/
Adalimumab
/
Anti-Inflamatórios
Tipo de estudo:
Health_economic_evaluation
Limite:
Humans
Idioma:
En
Revista:
Expert Rev Pharmacoecon Outcomes Res
Assunto da revista:
FARMACOLOGIA
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Canadá